Hyperornithinemia, hyperammonemia, homocitrullinuria syndrome

Hyperornithinemia, hyperammonemia, homocitrullinuria syndrome (HHH syndrome) is a rare genetic disorder affecting the urea cycle, a series of biochemical processes in humans. This syndrome is characterized by three primary conditions: elevated levels of ornithine (hyperornithinemia) in the blood, increased levels of ammonia (hyperammonemia), and the presence of homocitrulline in the urine (homocitrullinuria). The urea cycle is crucial for removing excess nitrogen from the body, which is produced during the breakdown of proteins. Disruptions in this cycle, such as those seen in HHH syndrome, can lead to the accumulation of toxic substances in the blood, particularly ammonia, which can cause serious health issues, including neurological damage.

Causes

HHH syndrome is caused by mutations in the SLC25A15 gene, which encodes for the mitochondrial ornithine transporter. This transporter is essential for the proper functioning of the urea cycle. The mutations lead to a dysfunction in the transport of ornithine into the mitochondria, resulting in the accumulation of ornithine, ammonia, and the formation of homocitrulline. HHH syndrome is inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to be affected by the disorder.

Symptoms

The symptoms of HHH syndrome can vary widely among affected individuals, ranging from mild to severe. Common symptoms include:

• Cognitive impairment
• Seizures
• Ataxia (lack of muscle coordination)
• Learning disabilities
• Hypotonia (reduced muscle tone)
• Lethargy
• Vomiting
• Coma in severe cases

Symptoms can be triggered or worsened by periods of stress, illness, or high protein intake, which increase the body's nitrogen load.

Diagnosis

Diagnosis of HHH syndrome typically involves a combination of biochemical tests and genetic testing. Biochemical tests may include blood and urine tests to measure levels of ammonia, ornithine, and homocitrulline. Genetic testing can confirm the presence of mutations in the SLC25A15 gene.

Treatment

There is no cure for HHH syndrome, but the condition can be managed with dietary restrictions and medications. Treatment typically involves a low-protein diet to reduce the intake of nitrogen and the use of medications such as sodium benzoate or sodium phenylbutyrate to help reduce blood ammonia levels. In some cases, arginine or citrulline supplements may be prescribed to support the urea cycle. Regular monitoring and management by a team of healthcare professionals, including a geneticist, neurologist, and dietitian, are essential for individuals with HHH syndrome.

Prognosis

The prognosis for individuals with HHH syndrome varies depending on the severity of the condition and the effectiveness of the management plan. Early diagnosis and treatment can improve the quality of life and reduce the risk of severe neurological damage.

Hyperornithinemia, hyperammonemia, homocitrullinuria syndrome Resources
Latest articles Most recent articles Ongoing trials	Wikipedia